To The Moon

$SPDR S&P Biotech ETF ( $Spdr S&P Biotech Etf(XBI)$ )$ $Pfizer ( $Pfizer(PFE)$ )$ $S&P 500(. $S&P 500(.SPX)$ )$ $Dow Jones Industrial Average(. $Dow Jones(.DJI)$ )$As of April 18, 2025, the U.S. stock market is reeling from a volatile week, with the S&P 500 shedding 2.8% on April 17 and the Dow Jones Industrial Average dropping 1,200 points in a single session. Fears of escalating trade tensions and a hawkish Federal Reserve have sparked widespread selling. Yet, amid the chaos, biotech stocks are staging an unexpected rally, driven by breakthrough drug approvals and M&A chatter. Is this a sector to

Healthcare giant $UnitedHealth(UNH)$ obliterated and is on track for its biggest loss in 27 years.Keydata: EPS of $7.20 missing expectations of $7.29, Revenue of $109.6B missing expectations of $111.6B.Why is $UNH down 23%? An amazing buying opportunityQ1 2025 Earnings Report AnalysisCompany OverviewUnitedHealth Group is a globally leading diversified healthcare company, operating primarily through two business segments: UnitedHealthcare (which provides health insurance and benefits services) and Optum (which offers information and technology-supported health services). The company is committed to helping people live healthier lives through innovative healthcare solutions and efficient operating models.Business and Business Model IntroductionUnited

It was roughly about a month ago that Wedbush Securities analyst Dan Ives warned Tesla CEO Elon Musk that patience among his shareholders was “wearing very thin”. It now looks as if it has finally snapped, after Wall Street’s most reliable $Tesla Motors(TSLA)$ bull slashed his price target nearly in half, blaming the polarizing CEO for poisoning the well. Moving forward, Ives said, EV sales for the brand that once hit breakneck speeds will only crawl ahead with percentage gains in the single digit as a result. “Demand destruction for Tesla and brand damage is real,” Ives wrote, “and has morphed into something much more concerning over the past few months.” By cutting his price target to $315 from $550, the Wedbush analyst broke ranks from many Tes